Sanat Chattopadhyay - 29 Apr 2025 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Reporting relationship: Exe V-P & Pres. MMD
Issuer ticker: MRK
Reported as of: 29 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 May 2025, 18:12:34 UTC
Prior SEC filing: 01 Apr 2025
Next SEC filing: 02 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Kelly E. W. Grez as Attorney-in-Fact for Sanat Chattopadhyay

Key filing fact

Sanat Chattopadhyay filed Form 4 for Merck & Co., Inc. (MRK) on 01 May 2025.

Key facts

This page summarizes Sanat Chattopadhyay's Form 4 filing for Merck & Co., Inc. (MRK).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 01 May 2025, 18:12.

Change

Previous filing in this sequence was filed on 01 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 7,000
Date: 29 Apr 2025
Ownership: By GRAT February 2024
Footnotes: F1

MRK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 50,622
Date: 29 Apr 2025
Ownership: By GRAT May 2024
Footnotes: F2

MRK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 53,417
Date: 29 Apr 2025
Ownership: By GRAT February 2025
Footnotes: F3

MRK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 74,289
Date: 29 Apr 2025
Ownership: By GRAT April 2025
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRK transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +7,791
Change %
Price: $0.000000
Shares after: 7,791
Date: 29 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,791
Exercise price
Footnotes: F5, F6

MRK transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +35,465
Change %
Price: $0.000000
Shares after: 35,465
Date: 29 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,465
Exercise price: $84.71
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

The reporting person serves as the sole trustee of, and maintains complete investment control over, the Sanat Chattopadhyay February 2024 Grantor Retained Annuity Trust.

Footnote F2

The reporting person serves as the sole trustee of, and maintains complete investment control over, the Sanat Chattopadhyay May 2024 Grantor Retained Annuity Trust.

Footnote F3

The reporting person serves as the sole trustee of, and maintains complete investment control over, the Sanat Chattopadhyay February 2025 Grantor Retained Annuity Trust.

Footnote F4

The reporting person serves as the sole trustee of, and maintains complete investment control over, the Sanat Chattopadhyay April 2025 Grantor Retained Annuity Trust.

Footnote F5

Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

Footnote F6

These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028.

Footnote F7

The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028.